|
TheraCryf PLC - Cheshire, England-based pharmaceutical firm focused on cancer and brain disorders - Says it started 2026 positively by reaching a key milestone towards clinical readiness for its orexin blocker Ox-1, a potential treatment for addictive disorders, by achieving the scale-up of the Ox-1 compound to 10 kilograms on schedule and with a yield exceeding expectations. Says this drug substance will be used in the 28-day regulatory toxicology studies scheduled to commence in two species during the first two quarters of this year. ‘These studies will provide essential data for the planned regulatory submission later in the year and represent the last major hurdle to achieving that goal,’ TheraCryf explains. Adds that work to complete maximum tolerated dose and dose range finding studies, which are necessary before commencing the 28-day toxicology studies. Says all studies are on schedule to be completed in the third quarter. Chief Operating Officer Helen Kuhlman says: ‘We are pleased to have achieved this key milestone in the development of our potentially class leading orexin blocker programme, on schedule. These activities are critical to generating a robust data package to enable human trials and we are on track to deliver them during 2026.’ Current stock price: 0.21 pence, up 5.0% on Monday in London 12-month change: down 72% Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
